1252003-15-8 Usage
Description
Tubastatin-A, also known as ChEBI, is a pyridoindole derivative with a unique chemical structure. It is characterized by its 1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indole core, which is substituted on the tetrahydropyridine nitrogen by a methyl group and on the indole nitrogen by a p-[N-(hydroxy)aminocarbonyl]benzyl group. Tubastatin-A is a selective histone deacetylase 6 (HDAC6) inhibitor, showing a high degree of specificity against other isozymes, with a 1000-fold selectivity over HDAC1 and a 57-fold selectivity over HDAC8.
Uses
Used in Pharmaceutical Industry:
Tubastatin-A is used as a histone deacetylase 6 (HDAC6) inhibitor for its potential therapeutic applications in various diseases. Its high selectivity for HDAC6 makes it a promising candidate for the development of targeted therapies, particularly in the treatment of cancer. By inhibiting HDAC6, Tubastatin-A can modulate gene expression and cellular processes, leading to the regulation of cell growth, differentiation, and apoptosis.
Used in Cancer Research:
In the field of cancer research, Tubastatin-A is used as a tool to study the role of HDAC6 in tumorigenesis and cancer progression. Its ability to selectively inhibit HDAC6 allows researchers to investigate the molecular mechanisms underlying the development and progression of various types of cancer. This knowledge can be used to identify novel therapeutic targets and develop more effective cancer treatments.
Used in Drug Development:
Tubastatin-A is used as a lead compound in the development of new drugs targeting HDAC6. Its unique chemical structure and high selectivity for HDAC6 make it an attractive starting point for the design and synthesis of new HDAC6 inhibitors. These new compounds can potentially exhibit improved potency, selectivity, and pharmacokinetic properties, leading to more effective treatments for various diseases, including cancer.
Used in Drug Delivery Systems:
Similar to gallotannin, Tubastatin-A can also benefit from novel drug delivery systems to enhance its applications and efficacy against cancer cells. Various organic and metallic nanoparticles can be employed as carriers for Tubastatin-A delivery, aiming to improve its delivery, bioavailability, and therapeutic outcomes. This approach can help overcome potential limitations associated with the drug's solubility, stability, and distribution within the body, ultimately leading to more effective treatments for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 1252003-15-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,2,0,0 and 3 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1252003-15:
(9*1)+(8*2)+(7*5)+(6*2)+(5*0)+(4*0)+(3*3)+(2*1)+(1*5)=88
88 % 10 = 8
So 1252003-15-8 is a valid CAS Registry Number.
1252003-15-8Relevant articles and documents
HDAC6 inhibitor accelerates wound healing by inhibiting tubulin mediated IL-1β secretion in diabetic mice
Ghosh, Balaram,Goli, Sriharshini,Karnam, Kalyani,Kulkarni, Onkar Prakash,Routholla, Ganesh,Sedmaki, Kavitha,Sharma, Pravesh,Venuganti, Venkata Vamsi Krishna
, (2020/08/06)
Delayed wound healing in diabetes is characterized by sustained activation of inflammasome and increased expression of IL-1β in macrophages. Identification and validation of novel pathways to regulate IL-1β expression will provide therapeutic targets for
